Aggregation Risk

Aggregation Risk for CJC-1295

Before a peptide becomes a purchase order, it pays to look hard at the sequence itself. EndoPhase gives you a read on the hydrophobic runs and motifs that tend to drive aggregation, for CJC-1295 and any sequence you are weighing up.

Run CJC-1295 preflight

Before a peptide becomes a purchase order, it pays to look hard at the sequence itself. For a candidate like CJC-1295, the questions worth answering early are practical: is the sequence clean to make, is it stable, and does the intended route even make sense. aggregation risk is the part of that picture EndoPhase focuses on here.

What aggregation risk looks at

For CJC-1295, EndoPhase surfaces a read on the hydrophobic runs and motifs that tend to drive aggregation, in plain language, with the reasoning kept beside the result so a reviewer can agree or push back.

Flagged risks specific to the CJC-1295 sequence, ranked by how much they matter.
A short rationale you can paste into a decision log or share with a reviewer.
A clean handoff to synthesis, with the assumptions written down.

Why do this before synthesis

Most wasted peptide budget is decided at the sequence stage, long before the lab gets involved. The whole idea is to spend judgement before spending budget. The point is simple: decide what is worth making before you make it.

Request beta access

CJC-1295 Preflight Scoring CJC-1295 Solubility Analysis CJC-1295 Synthesis Difficulty CJC-1295 Net Charge Profile CJC-1295 Hydrophobicity Assessment CJC-1295 Oral Delivery Outlook

EndoPhase is research-use software. It does not sell peptides, give medical advice, diagnose, treat, or make claims about the safety or efficacy of any compound named here. Names are used as analysis subjects only.